Board, E. (2021). PIK3CA mutation: Changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021. IP Habib O.N.
Style de citation Chicago (17e éd.)Board, Editorial. PIK3CA Mutation: Changing the Paradigm of HR+ HER2-negative Metastatic Breast Cancer Therapy. Review of the Novartis Pharma Satellite Symposium, Held as Part of a Virtual Forum Dedicated to the Diagnosis and Treatment of Patients with Hormone-dependent HER2-negative Advanced Breast Cancer with a PIK3CA Gene Mutation. April 23, 2021. IP Habib O.N, 2021.
Style de citation MLA (8e éd.)Board, Editorial. PIK3CA Mutation: Changing the Paradigm of HR+ HER2-negative Metastatic Breast Cancer Therapy. Review of the Novartis Pharma Satellite Symposium, Held as Part of a Virtual Forum Dedicated to the Diagnosis and Treatment of Patients with Hormone-dependent HER2-negative Advanced Breast Cancer with a PIK3CA Gene Mutation. April 23, 2021. IP Habib O.N, 2021.